New challenges in cancer personalized medicine: from identifying mutation to precise modification

Nowadays the genomic characterization of each tumor is a hopeful strategy for targeted therapies based on person-specific information, gain advances in precision medicine were made in human oncology. The combined efforts of specialists reveal significant progress in cancer genetic testing panels, now identified as Next Generation Sequencing (NGS) technology. NGS technology offers the ability to sequencing tumor causative mutations that allowing for more accurate targeting therapies. Moreover, development of CRISPR-Cas9 edition system to correct disease-related mutations and to activate or suppress involved genes, can be applied for therapeutic purposes. To date, preliminary evidence introduce adenine base editors (ABEs) system to correct point mutations more professional than Cas9 nuclease-based method in human cells and without double-stranded DNA cleavage. In this Progress article, we reviewed the linkage between using NGS as DNA sequencing technology and ABEs as advance genome editing with particular emphasis on the field of cancer. In conclusion, it may lead to development of individualized approaches that enable to precise medicine target.

کلیدواژه ها:

NGS ، CRISPR-Cas9 ، Cancer ، ABE ، personalized medicine